We are live on ! Find out more
BDSI

BioDelivery Sciences International, Inc.

Delisted

BDSI was delisted on the 22nd of March, 2022.

86 hedge funds and large institutions have $153M invested in BioDelivery Sciences International, Inc. in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

268% more call options, than puts

Call options by funds: $420K | Put options by funds: $114K

150% more funds holding in top 10

Funds holding in top 10: 25 (+3)

37% more capital invested

Capital invested by funds: $112M → $153M (+$41.3M)

17% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 18

4% more funds holding

Funds holding: 8386 (+3)

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

Holders
86
Holders Change
+3
Holders Change %
+3.61%
% of All Funds
1.92%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.11%
New
21
Increased
23
Reduced
24
Closed
18
Calls
$420K
Puts
$114K
Net Calls
+$306K
Net Calls Change
+$43K
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
51
BlueCrest Capital Management
Jersey
$181K +$171K +48,786 New
Bank of Montreal
52
Bank of Montreal
Ontario, Canada
$174K
RJA
53
Raymond James & Associates
Florida
$171K +$21.1K +6,000 +15%
ARTA
54
A.R.T. Advisors
New York
$165K -$61.5K -17,500 -28%
Bank of New York Mellon
55
Bank of New York Mellon
New York
$164K
AGM
56
Alpine Global Management
New York
$149K +$142K +40,376 New
Squarepoint
57
Squarepoint
New York
$147K +$139K +39,700 New
Janney Montgomery Scott
58
Janney Montgomery Scott
Pennsylvania
$137K +$2.02K +576 +2%
CCB
59
Cutter & Co Brokerage
Missouri
$131K
Morgan Stanley
60
Morgan Stanley
New York
$99K -$225K -64,072 -70%
Citadel Advisors
61
Citadel Advisors
Florida
$77K -$236K -67,216 -76%
Charles Schwab
62
Charles Schwab
California
$62K
VNA
63
Valley National Advisers
Pennsylvania
$61K -$22.2K -6,327 -28%
Goldman Sachs
64
Goldman Sachs
New York
$53K -$1.78K -506 -3%
UBS Group
65
UBS Group
Switzerland
$52K -$13.8K -3,926 -22%
Acadian Asset Management
66
Acadian Asset Management
Massachusetts
$48K +$8.09K +2,303 +22%
AG
67
Advisor Group
Arizona
$40K +$13.8K +3,943 +56%
SI
68
Stephens Inc
Arkansas
$37K
CAM
69
Close Asset Management
United Kingdom
$26K -$58.8K -16,750 -93%
CSS
70
Cubist Systematic Strategies
Connecticut
$22K -$20.8K -5,912 -50%
FCMT
71
Founders Capital Management (Texas)
Texas
$22K
LTFS
72
Ladenburg Thalmann Financial Services
Florida
$15K -$10.5K -3,000 -43%
AIC
73
Ameritas Investment Company
Nebraska
$11K +$10.2K +2,900 New
EARNEST Partners
74
EARNEST Partners
Georgia
$10K
IA
75
IFP Advisors
Florida
$8K -$2K -571 -19%

BDSI Hedge Fund Activity: Q4 2018 in Review

86 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in BioDelivery Sciences International, Inc. (BDSI) for Q4 2018, worth a combined $153M — up 37% from $112M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new BDSI positions and 18 closed out — a net gain of 3 holders — while 23 added to existing stakes and 24 trimmed.

The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $7.01M. The largest seller was Armistice Capital, exiting entirely with an estimated $9.22M sold.

  • 86 institutional investors held BioDelivery Sciences International, Inc. (BDSI) as of Q4 2018, up from 83 in Q3 2018.
  • Funds reported $153M of BioDelivery Sciences International, Inc. stock for Q4 2018, up 37% quarter-over-quarter.
  • 21 funds opened new BioDelivery Sciences International, Inc. positions in Q4 2018 and 18 closed out, a net change of +3 holders.
  • The largest BioDelivery Sciences International, Inc. buyer in Q4 2018 was Rubric Capital Management (New York), an estimated $7.01M added.
  • The largest BioDelivery Sciences International, Inc. seller in Q4 2018 was Armistice Capital, an estimated $9.22M sold.

Based on aggregated 13F filings for Q4 2018.